We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Atomic Force Microscopy Reveals Cell Stiffness as Potential Biomarker

By LabMedica International staff writers
Posted on 24 Oct 2012
New findings reveal that cell stiffness could be potential evidence for clinicians as they look for and treat cancerous cells before they are able to metastasize. More...
The research demonstrated that highly metastatic ovarian cancer cells are several times softer than less metastatic ovarian cancer cells.

Georgia Institute of Technology (Georgia Tech; Atlanta, USA) assistant professor Dr. Todd Sulchek and PhD student Wenwei Xu used technology called atomic force microscopy (AFM) to examine the mechanical characteristics of various ovarian cell lines. A soft mechanical probe “tapped” healthy, malignant, and metastatic ovarian cells to measure their stiffness.

The study‘s findings were published October 4, 2012, in the journal PLoS One. “In order to spread, metastatic cells must force themselves into the bloodstream. As a result, they must be highly deformable and softer,” said Dr. Sulchek, a faculty member in the George W. Woodruff School of Mechanical Engineering. “Our results indicate that cell stiffness may be a useful biomarker to evaluate the relative metastatic potential of ovarian and perhaps other types of cancer cells.”

Just as earlier research on other types of epithelial cancers have indicated, Dr. Sulchek also discovered that cancerous ovarian cells are generally softer and display lower intrinsic variability in cell stiffness than nonmalignant cells. Dr. Sulchek’s lab collaborated with Prof. John McDonald, who is also director of Georgia Tech’s newly established Integrated Cancer Research Center. “This is a good example of the kinds of discoveries that only come about by integrating skills and knowledge from traditionally diverse fields such as molecular biology and bioengineering,” said Prof. McDonald. “Although there are a number of developing methodologies to identify circulating cancer cells in the blood and other body fluids, this technology offers the added potential to rapidly determine if these cells are highly metastatic or relatively benign.”

Dr. Sulchek and Prof. McDonald hope that, when further modified, this technology could offer a great benefit to clinicians in the creation of optimal chemotherapies, for ovarian cancer patients and patients of other types of cancer.

Related Links:

Georgia Institute of Technology



Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
Urine Analyzer
respons® UDS100
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Characterization of EV separated by distinct methods (Photo courtesy of Yuanyuan Liu, Yanbin Guo et al. Engineering, doi.org/10.1016/j.eng.2025.12.009)

Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis

Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read more

Molecular Diagnostics

view channel
Image: Associate Professor Arutha Kulasinghe and non-small cell lung cancer cell (Photo courtesy of The University of Queensland)

Blood-Based Proteomic Test May Predict Treatment Response in Non-Small Cell Lung Cancer

Lung cancer remains the leading cause of cancer death, with non-small cell lung cancer (NSCLC) accounting for most cases. Treatment decisions are often made without a clear indication of how a patient... Read more

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.